Equities researchers at Oppenheimer Holdings, Inc. assumed coverage on shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) in a note issued to investors on Thursday. The firm set an “outperform” rating and a $12.00 price target on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price objective would suggest a potential upside of 81.82% from the company’s previous close.
Several other analysts have also weighed in on SBBP. Zacks Investment Research lowered shares of Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th. HC Wainwright reaffirmed a “buy” rating on shares of Strongbridge Biopharma PLC in a report on Wednesday, May 17th. Finally, ValuEngine raised shares of Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $11.94.
Shares of Strongbridge Biopharma PLC (NASDAQ SBBP) traded down 3.65% during trading on Thursday, reaching $6.60. The company had a trading volume of 54,942 shares. Strongbridge Biopharma PLC has a 12-month low of $2.00 and a 12-month high of $8.85. The firm has a 50-day moving average of $6.76 and a 200-day moving average of $4.58. The company’s market cap is $233.21 million.
Strongbridge Biopharma PLC (NASDAQ:SBBP) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34). The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.84 million. On average, equities research analysts anticipate that Strongbridge Biopharma PLC will post ($2.20) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2799738/strongbridge-biopharma-plc-sbbp-receives-new-coverage-from-analysts-at-oppenheimer-holdings-inc.html.
Several hedge funds have recently modified their holdings of SBBP. State of Wisconsin Investment Board bought a new stake in shares of Strongbridge Biopharma PLC during the second quarter worth $114,000. Rhumbline Advisers bought a new stake in shares of Strongbridge Biopharma PLC during the second quarter worth $154,000. Teachers Advisors LLC bought a new stake in shares of Strongbridge Biopharma PLC during the second quarter worth $297,000. Bank of New York Mellon Corp bought a new stake in shares of Strongbridge Biopharma PLC during the second quarter worth $331,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in shares of Strongbridge Biopharma PLC during the second quarter worth $332,000.
About Strongbridge Biopharma PLC
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.